CRSP vs PACB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRSP Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | PACB Revenue | CRSP Op. Margin | PACB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $80M | -5087.8% | -128.4% | PACB |
| FY2019 | $290M | $90M | 16.1% | -110.6% | CRSP |
| FY2020 | $0M | $80M | -49295.5% | -132.3% | PACB |
| FY2021 | $910M | $130M | 40.8% | -161.2% | CRSP |
| FY2022 | $0M | $130M | -56190.4% | -239.4% | PACB |
| FY2023 | $370M | $200M | -60.0% | -166.8% | CRSP |
| FY2024 | $40M | $150M | -1250.4% | -308.0% | PACB |
| FY2025 | $0M | $160M | -18933.6% | -346.2% | PACB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | PACB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $615.1M | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | +5.5% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | -333.0% | Higher Margin | PACB |
| Net Profit Margin Profitability | 0.0% | -81.3% | Higher Margin | CRSP |
| Return on Equity (ROE) Capital Efficiency | -25.6% | -929.3% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 34% ($1โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | 2.27ฮฒ ยท 112% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 38.0 / 100 (SELL) | Higher Composite | CRSP |